Novo Nordisk’s ‘strategic conundrum’: How being anchored to the past could cost it the futurenews2026-02-27T12:11:21+00:00February 27th, 2026|Endpoints News|
Doug Ingram’s uneven legacy at Sarepta; Merck splits human health business, brings in Sanofi execnews2026-02-27T12:00:10+00:00February 27th, 2026|Endpoints News|
DOJ urges Supreme Court to undo revival of Hikma ‘skinny label’ case news2026-02-26T20:42:26+00:00February 26th, 2026|Endpoints News|
Doug Ingram’s force of will meets its match as Sarepta CEO plans to depart news2026-02-26T20:17:18+00:00February 26th, 2026|Endpoints News|
FDA probes internal Prasad complaints with outside helpnews2026-02-26T20:13:02+00:00February 26th, 2026|Endpoints News|
Boehringer wins accelerated approval for first-line use of lung cancer drugnews2026-02-26T20:03:47+00:00February 26th, 2026|Endpoints News|
Senate hearing raises FDA-related concerns for new rare disease drugsnews2026-02-26T19:27:02+00:00February 26th, 2026|Endpoints News|
Viatris plans to lay off up to 10% of staff, discloses Indian factory fire news2026-02-26T18:09:12+00:00February 26th, 2026|Endpoints News|
Why did my doctor push Grail’s dubious cancer test?news2026-02-26T17:09:28+00:00February 26th, 2026|Endpoints News|
AtaiBeckley stock drops on Phase 2a data; Disc to refile rare disease drugnews2026-02-26T16:06:55+00:00February 26th, 2026|Endpoints News|
